Commercialization by at least a handful of ClearPoint Neuro's partners should make its shares 10x higher over ten years. x.com 

ClearPoint Neuro has many irons in the fire beyond uniQure, one of its 60+ partners, which still has a decent probability of BLA acceptance in November. Neurona's MTLE drug and Parkinson's partners are enrolling, and gene and cell therapy delivered into the brain is not going to slow down. x.com 

ClearPoint Neuro looks expensive against its sales, at 11x trailing and 8x next year's sales versus the roughly 5x medical-device makers usually get. Fair value is $7.16 to $9.11, about 5x next year's sales give or take 12%, putting the $13.83 price 52% above fair. The valuation leans on forecasts, with forward sales 40% above trailing. This is a levels-only read off reported earnings and revenue estimates, with no fundamental work. x.com 

uniQure's AMT-130 likely still gets approved and can be a reasonable commercial success. The open questions are insurance coverage and pricing, and whether Huntington's disease patients will pay given there is no other treatment. x.com 

uniQure's risk/reward is attractive because $10-12 of cash per share plus the upside implies the market assigns a low chance of approval. Management communication was the core issue rather than a change to the endgame; the unmet need is huge and the company is likely closer to the finish line than the start. The prespecified cUHDRS base and bull case was missed, possibly because of attrition, but being negative here is fundamentally betting the drug doesn't work. x.com 

ClearPoint Neuro consistently disappoints on multiple levels, and other stocks don't. Its business is hard to forecast and build, and quarterly or annual guides are not how real businesses run, but the misses keep coming. @StockDaddy6597 notes repeated guide-downs and slipping timelines, with GLP readiness pushed from end-2025 to 2026 and big study wins now expected in late 2027. x.com